The product of the dek oncogene is the 43-kDa DEK nuclear protein. DEK was first identified in a fusion with the CAN nucleoporin protein in a specific subtype of acute myelogenous leukemia. DEK has also been shown to be an autoantigen in patients with pauciarticular onset juvenile rheumatoid arthritis. Further, the last 65 amino acids of DEK can partially reverse the mutation-prone phenotype of cells from patients with ataxia-telangiectasia. However, in spite of these significant disease associations, the function of DEK has remained unclear. The HIV-2 peri-ets (pets) site is a TG-rich element found between the two Elf-1 binding sites in the HIV-2 enhancer. The pets element mediates transcriptional activation whether the enhancer is stimulated by phorbol 12-myristate 13-acetate (PMA) alone, phytohemagluttinin (PHA) alone, PMA plus PHA, soluble antibodies to the T cell receptor, immobilized antibodies to the T cell receptor, or by antigen. Previously, we purified and characterized the pets factor, demonstrating that it is a 43-kDa nuclear protein. We now describe the identification of DEK as this 43-kDa pets factor. Using a modified Southwestern screening procedure, we find that DEK can recognize the pets element. We demonstrate the ability of recombinant DEK to bind specifically to the pets site using the electrophoretic mobility shift assay (EMSA) and DNase I footprinting. ''Supershift'' EMSA further confirms that DEK is the dominant protein binding to the pets site in T cell extracts. Our findings show that DEK is a site-specific DNA binding protein that is likely involved in transcriptional regulation and signal transduction. This has implications for multiple pathogenic processes, including hematologic malignancies, arthritis, ataxia-telangiectasia, and AIDS caused by HIV-2.A (6;9) chromosomal translocation is associated with a specific subtype of acute myelogenous leukemia (AML) (1-3). This translocation results in the fusion of two genes, dek and can, and the expression of a leukemia-specific, chimeric dek-can mRNA and fusion protein (1). How this 165-kDa chimeric protein might lead to leukemia has been unclear, however. It has recently been shown that CAN is a nucleoporin, and it has therefore also been termed nup214 (nucleoporin of 214 kDa; ref. 4). The 3Ј portion of CAN can form a fusion protein not only with DEK, leading to AML, but also with the SET protein, leading to undifferentiated leukemia (2). One group has shown that CAN localizes exclusively to the cytoplasmic side of the nuclear pore complex (4). A second group has demonstrated that, when CAN is overexpressed, it is found not only on the cytoplasmic side of the nuclear membrane, but also on the nucleoplasmic side (5). Like their normal counterparts DEK and SET, DEK-CAN, and SET-CAN were localized exclusively to the nucleus. It was concluded that the relocation of the carboxyl-terminal portion of CAN from the nuclear envelope to the nucleoplasm may reinforce a nuclear function of CAN (5), implying that this relocation plays a role in l...